Skip to main content

HIV And Aging Clinical Recommendations: Cancer in HIV and Aging

AAHIVM Course Banner
0.75 CEUs
HIV and Aging Clinical Recommendations
Cancer in HIV and Aging

Module Description If there is one constant in the field of HIV medicine, it is that of constant change. The science of HIV is an ever-changing landscape of new research findings, new medications with new targets and also new side effects. In addition to new populations affected by the epidemic, as the elderly, there is the ever-demanding goal of seeking an actual cure for HIV disease. People with HIV have been found to be particularly at risk for cancers associated with infections including anal, vaginal, penile, nasopharyngeal, laryngeal, and oral cancer related to HPV; liver cancer related to viral hepatitis; and cancers associated with smoking. 

Credit Dates 06/08/21 – 06/07/22

Jointly provided by Postgraduate Institute for Medicine and the American Academy of HIV Medicine.

This activity is supported by independent medical education grants from Gilead Sciences, Janssen Therapeutics and ViiV Heatlthcare. 
Learning Objectives
  • Incorporate best practice strategies for screening and detection of HIV in older adults.
  • Incorporate into clinical practice, novel strategies for long-term management of HIV disease in older patients, including when to start ART and preferred regimens for this population
  • Utilize best practice strategies to care for and treat common co-morbid conditions of older age in HIV, such as CVD, cancers, dementia, depression, diabetes mellitus, and metabolic syndrome

Target Audience
This activity is intended for physicians, physician assistants, nurse practitioners, registered nurses and pharmacists who are engaged in the care of patients with HIV and/or gerontology.

Presenter
Meredith Green, MD
UCSF School of Medicine
San Francisco, CA

Method of Participation and Requeset for Credit
There are no fees for participating and receiving CME/CE credit for this activity.

During the period June 8, 2021 through June 7, 2022, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 16415. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within four weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com or visit www.pimed.com.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com or visit www.pimed.com. In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the American Academy of HIV Medicine. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education Credit The Postgraduate Institute for Medicine designates this internet activity for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education The Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of Accreditation Council for Pharmacy Education (Universal Activity #JA4008162-9999-21-2811-H02-P). Type of Credit: Knowledge

Continuing Nursing Education The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

Disclosure of Conflict of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty
Dr. Greene receives grant funding from Gilead Sciences, Inc. 

Planners and Managers
The PIM planners and managers have nothing to disclose. The Academy managers have nothing to disclose.

Media: Internet

Computer System Requirements: This program requires the use of an internet-connected computer or device and a modern web browser capable of displaying PDFs.    

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.